SAR-443579

Innate Pharma has initiated a Phase 1 clinical trial (NCT06781983) to evaluate the safety and tolerability of IPH4502 in patients with advanced solid tumors expressing Nectin-4.

Innate Pharma reported positive Phase 2 results for lacutamab in mycosis fungoides, engaging with the FDA for potential accelerated approval.

Sanofi will showcase new data from its oncology pipeline at the ASCO 2023 Annual Meeting, including a first-in-human study of SAR443579, a novel NK cell engager for hematological malignancies, which has received Fast Track Designation by the U.S. FDA.